Cancer Patients Face Uncertainty as Deadly Postcode Lottery Leaves Them Without Access to Life-Saving Treatments
In a shocking revelation, doctors have warned that patients in England are being denied access to cutting-edge cancer treatments due to a "deadly postcode lottery" imposed by the NHS. The treatments, including stereotactic ablative body radiotherapy (SABR) and molecular radiotherapy (MRT), are proven to be effective but remain largely inaccessible to those living in certain areas.
According to the Royal College of Radiologists (RCR) and Radiotherapy UK, hospitals that want to provide these innovative treatments face "bureaucratic hurdles" due to complex funding and commissioning policies imposed by NHS England. This has resulted in only half of cancer centres in England being able to offer surface-guided radiation therapy (SGRT), a technology that uses real-time 3D cameras to make radiotherapy more accurate.
The situation is further complicated by the fact that hospitals can only provide SABR for certain types of cancer, such as lung cancer, due to the archaic nature of the NHS's "tariff" system. This means that hospitals will lose money if they use SABR for other types of cancer apart from lung cancer.
"This is a tragedy of unprecedented proportions," said Dr Nicky Thorp, vice-president for clinical oncology at the RCR. "We know how to fix this, but bureaucracy and broken funding systems keep us from making progress."
The lack of access to these life-saving treatments has led to poor cancer survival rates in England, with many patients being forced to seek treatment abroad or pay privately.
"The NHS is supposed to be a national health service, but that's not true if access to modern radiotherapy depends on where you live," said Pat Price, chair of Radiotherapy UK and professor of oncology at Imperial College London. "This postcode lottery is unacceptable."
The government's new cancer plan, being published this week, has been welcomed by the RCR and Radiotherapy UK as an opportunity to address these issues and make innovative treatments more widely available.
However, critics argue that it remains to be seen whether the plan will deliver on its promise and actually increase access to these life-saving treatments.
In a shocking revelation, doctors have warned that patients in England are being denied access to cutting-edge cancer treatments due to a "deadly postcode lottery" imposed by the NHS. The treatments, including stereotactic ablative body radiotherapy (SABR) and molecular radiotherapy (MRT), are proven to be effective but remain largely inaccessible to those living in certain areas.
According to the Royal College of Radiologists (RCR) and Radiotherapy UK, hospitals that want to provide these innovative treatments face "bureaucratic hurdles" due to complex funding and commissioning policies imposed by NHS England. This has resulted in only half of cancer centres in England being able to offer surface-guided radiation therapy (SGRT), a technology that uses real-time 3D cameras to make radiotherapy more accurate.
The situation is further complicated by the fact that hospitals can only provide SABR for certain types of cancer, such as lung cancer, due to the archaic nature of the NHS's "tariff" system. This means that hospitals will lose money if they use SABR for other types of cancer apart from lung cancer.
"This is a tragedy of unprecedented proportions," said Dr Nicky Thorp, vice-president for clinical oncology at the RCR. "We know how to fix this, but bureaucracy and broken funding systems keep us from making progress."
The lack of access to these life-saving treatments has led to poor cancer survival rates in England, with many patients being forced to seek treatment abroad or pay privately.
"The NHS is supposed to be a national health service, but that's not true if access to modern radiotherapy depends on where you live," said Pat Price, chair of Radiotherapy UK and professor of oncology at Imperial College London. "This postcode lottery is unacceptable."
The government's new cancer plan, being published this week, has been welcomed by the RCR and Radiotherapy UK as an opportunity to address these issues and make innovative treatments more widely available.
However, critics argue that it remains to be seen whether the plan will deliver on its promise and actually increase access to these life-saving treatments.